Cognition Therapeutics, Inc. https://cogrx.com Fri, 27 Mar 2026 19:09:49 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 https://cogrx.com/wp-content/uploads/2019/03/cropped-COGRX-sq-for-outlook-32x32.jpg Cognition Therapeutics, Inc. https://cogrx.com 32 32 AD/PD 2026 | Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB https://cogrx.com/adpd2026-vjdementia-findings-from-phase2a-shimmer-trial-in-dlb/ Tue, 10 Mar 2026 18:58:36 +0000 https://cogrx.com/?p=13419 AD/PD 2026 | Findings from the Phase 2a SHIMMER trial of zervimesine in mild-to-moderate DLB Video Journal of Dementia March 10, 2026]]> AD/PD 2026 | Findings from the Phase 2a SHIMMER trial of zervimesine in mild-to-moderate DLB Video Journal of Dementia March 10, 2026]]> Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB) https://cogrx.com/phase-2-shimmer-study-of-zervimesine-in-mild-to-moderate-dlb/ Tue, 06 Jan 2026 20:24:31 +0000 https://cogrx.com/?p=13378 Galvin JE, Tolea MI, Scharre DW, et al. Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB). Alzheimer’s Dement. 2025;21:e71004;

]]> Alzheimer’s Disease Pivotal Trial Design for Zervimesine Following an End-of-Phase 2 Meeting with FDA https://cogrx.com/alzheimers-disease-pivotal-trial-design-for-zervimesine-following-an-end-of-phase-2-meeting-with-fda/ Mon, 01 Dec 2025 15:46:37 +0000 https://cogrx.com/?p=13372 Iaci JF, Grundman M, Hernandez NAS, et al. Alzheimer’s Disease Pivotal Trial Design for Zervimesine Following an End-of-Phase 2 Meeting with FDA. Poster presentation at 2025 Clinical Trials in Alzheimer’s Disease (CTAD); San Diego, CA

]]> Sigma-2 Receptor Modulators Alter Low-density Lipoprotein Receptor-mediated Lipid Uptake in Retinal Pigment Epithelial Cells https://cogrx.com/sigma-2-modulators-alter-ldl-receptor-mediated-lipid-uptake-in-rpe/ Wed, 27 Aug 2025 12:51:49 +0000 https://cogrx.com/?p=13363 Lizama BN, Reaver A, Look G, et al. Sigma-2 Receptor Modulators Alter Low-density Lipoprotein Receptor-mediated Lipid Uptake in Retinal Pigment Epithelial Cells. Experimental Eye Research. 2026 Feb; online ahead of print. https://doi.org/10.1101/2025.08.22.670986

]]> Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s https://cogrx.com/zervimesine-shows-129-percent-arrest-of-cognitive-decline-in-mild-alzheimers/ Wed, 30 Jul 2025 20:29:32 +0000 https://cogrx.com/?p=13351 Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s Clinical Trials Arena By Abigail Beaney July 30, 2025]]> Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s Clinical Trials Arena By Abigail Beaney July 30, 2025]]> Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease https://cogrx.com/zervimesine-for-the-treatment-of-dementia-with-lewy-bodies-and-alzheimers-disease/ Tue, 29 Jul 2025 13:34:07 +0000 https://cogrx.com/?p=13353 New Data: Zervimesine for the Treatment of Dementia with Lewy Bodies and Alzheimer Disease Psychiatric Times By Leah Kuntz July 29, 2025]]> New Data: Zervimesine for the Treatment of Dementia with Lewy Bodies and Alzheimer Disease Psychiatric Times By Leah Kuntz July 29, 2025]]> Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies https://cogrx.com/phase-2-study-of-zervimesine-ct1812-in-mild-to-moderate-dementia-with-lewy-bodies/ Tue, 29 Jul 2025 11:30:40 +0000 https://cogrx.com/?p=13350 Galvin JE, Hambe ME, Iaci JF, et al. Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies. Podium presentation at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

]]> Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement https://cogrx.com/exploratory-csf-proteomic-analysis-of-a-pre-specified-ptau217-subgroup-from-the-shine-clinical-trial-identifies-biomarkers-correlated-with-cognitive-improvement/ Sun, 27 Jul 2025 11:00:59 +0000 https://cogrx.com/?p=13343 Lizama BN, Pandey K, Cho E, et al. Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement in Alzheimer’s Disease Patients Treated with Zervimesine. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

]]> Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum https://cogrx.com/zervimesine-treatment-benefits-patients-with-lower-baseline-plasma-p-tau217-across-the-mild-to-moderate-alzheimers-disease-spectrumo-moderate-ad-spectrum/ Sun, 27 Jul 2025 11:00:06 +0000 https://cogrx.com/?p=13348 Grundman M, Catalano S, Hamby ME, et al. Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

]]> Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in GFAP https://cogrx.com/plasma-proteomic-analysis-of-a-biomarker-defined-subpopulation-in-the-shine-ph2-trial-to-identify-molecular-correlates-to-the-favorable-decrease-in-gfap/ Sun, 27 Jul 2025 11:00:02 +0000 https://cogrx.com/?p=13344 Lizama BN, DiCaro V, Cho E, et al. Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial
to Identify Molecular Correlates to the Favorable Decrease in the Neuroinflammatory Marker GFAP with Zervimesine in Alzheimer’s Disease Participants. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

]]>